SUMMARY The percutaneous absorption of chlorhexidine during its routine use in topical antiseptic preparations used in umbilical cord care was investigated by determining plasma chlorhexidine concentrations at ages 5 and 9 days. These showed that percutaneous absorption of chlorhexidine occurred in preterm neonates treated with a 1 % solution of chlorhexidine in ethanol, but not in term infants similarly treated, or in preterm infants treated only with a dusting powder containing 1 % chlorhexidine and 3 % zinc oxide. 
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Chlorhexidine (CHD) (1, 6 -di (4-chlorophenyldiguanido) hexane) (Hibitane ICI Ltd UK) is a topical antiseptic which has a wide activity against Gram-positive and Gram-negative bacteria and some yeasts.1 Its ability to disinfect skin2 and reduce newborn staphylococcal infection3 is comparable with that of hexachlorophane (HCP). The demonstration of percutaneous absorption of HCP, of its neurotoxicity in man and animals, and the subsequent realisation of the risk incurred by its excessive application to injured skin or to the intact skin of preterm newborn babies has been reviewed.4 5 Restrictions on the routine use of HCP led to The increasing plasma CHD levels in the preterm infants of Study A and the absence of this feature in those infants from Study B, who were only exposed to CHD zinc oxide dusting powder for routine cord care, suggests that the repeated use of the ethanol CHD solution was responsible for percutaneous absorption of CHD by the preterm babies in the first study.
The humidity within an incubator and exposure to phototherapy may increase cutaneous vascular perfusion thereby enhancing skin permeability. These factors were more prevalent in the second study and were probably therefore of less significance than ethanol in influencing percutaneous absorption of CHD, but we cannot exclude the possibility that such factors might have contributed to the presence of detectable plasma CHD in one of the infants from Study B. The significant plasma CHD concentrations in the other 3 infants from the second 
